The Resmed CDI (ASX: RMD) share price is down 4% after reporting its FY26 fourth quarter to investors.
ResMed is a healthcare company that helps people with sleep apnea, with devices including CPAP solutions and software.
FY26 fourth quarter
The company announced to the market how it performed in the three months to 30 June 2026.
Its FY26 fourth quarter revenue grew by 9% to $1.5 billion, while there was 8% growth on a constant currency basis. There was strong demand across sleep devices, masks, accessories and software solutions.
It revealed Americas sleep and breathing health revenue grew 8%, while the rest of the world sleep and breathing health rose 10% in constant currency terms. Residential care software revenue grew 2% in constant currency terms.
The healthcare company reported that its gross profit margin improved by 90 basis points (0.90%), which is another good sign of profitability.
ResMed reported statutory earnings per share (EPS) growth of 2% to $2.64, while underlying (non-GAAP) EPS rose 16% to $2.95.
The business reported a quarterly cash dividend of $0.66 per share, representing an increase of 10% year on year.
With the completion of that quarter, ResMed was able to tell investors about the performance of its annual FY26 result.
FY26 result
The below are largely statutory (GAAP) figures, unless stated:
- Revenue grew 10% to $5.7 billion
- Gross profit margin increased 170 basis points (1.70%) to 61.1%
- Operating profit margin up 70 basis points (0.70%) to 33.4%
- Operating profit up 16% to $2.04 billion
- Underlying (non-GAAP) EPS grew 17% to $11.17, with GAAP EPS of $10.43 (up 10%)
- Net profit grew 9% to $1.5 billion
- Operating cashflow up 3% to $1.8 billion
- Free cashflow down 1% to $1.65 billion
Outlook for the ResMed share price
ResMed said that as it enters FY27, it will “leverage its global scale and enhance” its digital capabilities to benefit patients, providers and customers.
The company said it’s aiming to improving patient outcomes, reduce healthcare costs and drive long-term profitable growth for shareholders.
The ResMed share price is down 30% in the past year and 4% today, so investors haven’t loved what they’ve seen from the business. Clearly, they were expecting more.
I’m not sure I’d call the business cheap, but I do think it has a promising future. It’s not one of the first ASX growth shares I’d buy today, but I’d be happy enough with the reported numbers if I were a shareholder.
